

---

**FerriScan® Now Available on 3 Tesla (3T) MRI Scanning Machines**

---

**Highlights**

- FerriScan® now available on 3 tesla (3T) magnetic field strength MRI machines.
- 3T MRI machines are the newer generation of MRI scanning machines and are prevalent in hospitals and MRI centres globally, with increasing popularity and usage.
- Availability of FerriScan® on 3T MRI machines is a key element of Resonance Health's strategy to grow diagnostic and clinical trial contracts and revenue.
- Work to adapt FerriSmart® (AI evolution of FerriScan®) to 3T MRI machines is advancing.
- FerriScan® remains the global gold standard for assessment of liver iron concentration (LIC).

**FerriScan® now available on 3 tesla (3T) MRI machines**

Resonance Health Ltd (ASX: RHT) ("Resonance Health" or the "Company") is pleased to advise that FerriScan®, its flagship product, is now available for use on 3T MRI scanning machines.

**The gold standard in liver iron concentration measurement**

FerriScan® is internationally recognised by clinicians as the gold standard for the measurement of liver iron concentration ("LIC") for patients suffering iron overload disorders. This accurate MRI-based technique is non-invasive and eliminates the need for liver biopsies. FerriScan® is recommended in multiple clinical patient management guidelines and international standards of care.

Since the Company's inception, Resonance Health has completed over 58,000 FerriScan® analyses to assist patients suffering iron overload disorders around the world. Until now, the FerriScan® service has only been available at MRI facilities with 1.5 tesla (1.5T) field strength MRI machines.

**Development of FerriScan® for 3T MRI machines**

The Company commenced studies aiming to adapt the FerriScan® acquisition protocol from 1.5T to 3T MRI scanners, which would allow for better usability of the FerriScan® service across a broader range of MRI machines.

Resonance Health is pleased to advise that it recently successfully finalised the calibration of the FerriScan® protocol, with FerriScan® now commercially available for use in clinical trials and in the routine clinical management of patients, on both 1.5T and 3T MRI machines.

**Prevalence of 3T MRI machines and market opportunity**

3T MRI machines offer advantages for clinicians and patients, including shorter scan times and greater image contrast compared with 1.5T MRI machines, and are growing in prevalence around the world. In the United States, 1.5T and 3T scanners are now being purchased in approximately equal numbers and dominate new sales, with 3T scanners already representing approx. 15% to 18% of total MRI scanners in Europe and North America.<sup>1</sup>

---

<sup>1</sup> Could Very Low Field Strength Be the Next Frontier for MRI?, Burhan Ahmed Khan, M.D., Hyperfine intern, Eliot L. Siegel, M.D., Associate Vice Chair, University of Maryland School of Medicine, *Diagnostic Imaging*, 11 March 2021

Resonance Health is committed to ensuring its services - including FerriScan® - remain at the forefront of technical development and are available to as many patients as possible, so that their diseases can be managed effectively by their treating physicians.

Ensuring that FerriScan® is available on as many MRI machines as possible is also a key element of the Company's strategy to grow its clinical trial services contracts and revenue. Approximately 38% of Resonance Health's revenue is derived from providing analysis and other services to pharmaceutical companies undertaking clinical trials for treatments of iron overload and other disorders.

#### **Further development - FerriSmart® for 3T**

Work also continues to progress the adaptation of FerriSmart®, the Company's Artificial Intelligence ("AI") evolution of FerriScan®, to 3T MRI scanning machines. This will further enhance availability and convenience for clinicians and patients in large new markets.

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Limited.

For further information please contact:

**Mitchell Wells**

Managing Director, Resonance Health Ltd

E: [mitchellw@resonancehealth.com](mailto:mitchellw@resonancehealth.com)

P: +61 (0)8 9286 5300

## About Resonance Health

Resonance Health is an Australian healthcare technology and services company, specialising in the development and delivery of non-invasive medical imaging software and services.

The Company's products are used globally by clinicians in the diagnosis and management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for consistently providing high quality quantitative measurements essential in the diagnosis and management of diseases.

Resonance Health's dedication to scientific rigour and quality management has enabled it to achieve regulatory clearances for a range of Software as a Medical Device (**SaMD**) products in the USA, Europe, and Australia and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Some of the SaMD products incorporate the use of Artificial Intelligence (**AI**):

- **FerriScan®** a core-lab product that provides accurate measurement of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®** an AI-driven, non-invasive MRI-based device for the automated real-time measurement of LIC in patients.
- **HepaFat-AI®** an AI-driven, non-invasive MRI-based device for the automated real-time multi-metric measurement of liver fat in patients, for use in the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®** an AI-driven, non-invasive MRI-based multi-parametric device that combines FerriSmart® and HepaFat-AI® into a consolidated report that provides accurate measurement of liver iron concentration and liver fat.
- **CardiacT2\*** the most widely accepted MRI-based method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2\*. CardiacT2\* has regulatory clearance from the TGA and CE marking.

The Company has an active development pipeline of additional medical imaging analysis products and services, including, **LungSmart®** and **Alert-PE™**; AI tools for the automated review of chest CT scans of patients with cystic fibrosis and suspected pulmonary embolism, respectively.

Stakeholders including clinicians and patients are encouraged to follow Resonance Health on Facebook, LinkedIn, and Twitter.

